23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...

The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special ...

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...